Hyderabad, India and Princeton, NJ, USA. April 5, 2022 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL® (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA). The SOLU-MEDROL® brand and generic had U.S. sales of approximately $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health*. Dr. Reddy’s Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial,125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.
Click here for full prescribing information: https://www.drreddys.com/pil/dr_reddys_methylprednisolone_for_injection_package_insert.pdf
SOLU-MEDROL is a trademark of Pharmacia & Upjohn Company LLC
*IQVIA Retail and Non-Retail MAT February 2022
RDY-0322-401
